# Phase 1 Carcinoma, Transitional Cell trials: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials in phase 1 for Carcinoma, Transitional Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Carcinoma, Transitional Cell trials: 25 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/carcinoma-transitional-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 25
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 8, 2026 | NCT07807345 | Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic | Sutro Biopharma, Inc. | Phase 1 | Recruiting | Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Colorectal Cancer... | 285 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807345) |
| July 15, 2026 | NCT07705035 | DBC-664 in Adult Patients With Solid Tumors | Duboce Biopharmaceuticals, Inc. | Phase 1 | Recruiting | Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma... | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705035) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| April 29, 2026 | NCT07555769 | Calcium Electroporation for Urinary Bladder Tumors: A First-in-Human Feasibility, Safety, and Early Response Trial | Sponsor not shown (see the record) | Phase 1 | Recruiting | Bladder Tumors, Bladder Tumor, Urothelial Carcinoma (UC), Urothelial Carcinoma Bladder | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555769) |
| April 16, 2026 | NCT07532902 | A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma, Urothelial Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07532902) |
| April 8, 2026 | NCT07518043 | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors | Shanghai Henlius Biotech | Phase 1 | Recruiting | Esophageal and/or Cardia Cancer, Melanoma, Urothelial Carcinoma (UC) | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07518043) |
| March 25, 2026 | NCT07492628 | Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma | Beijing Biotech | Phase 1 | Recruiting | Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Upper... | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07492628) |
| March 19, 2026 | NCT07484022 | Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer | Generate Biomedicines | Phase 1 | Recruiting | Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07484022) |
| February 17, 2026 | NCT07416123 | A Study of GEN1106 in Participants With Solid Tumors | Genmab | Phase 1 | Recruiting | Solid Tumors, Urothelial Carcinoma | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07416123) |
| January 12, 2026 | NCT07334119 | Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors | Myeloid Therapeutics | Phase 1 | Recruiting | HER2-Expressing Solid Tumors | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07334119) |
| December 11, 2025 | NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | IDEAYA Biosciences | Phase 1 | Recruiting | NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell... | 260 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07277413) |
| October 16, 2025 | NCT07217496 | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer | ImmunityBio, Inc. | Phase 1 | Not yet recruiting | Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217496) |
| July 29, 2025 | NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | Pfizer | Phase 1 | Recruiting | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma... | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07090499) |
| May 31, 2025 | NCT06999187 | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | Sponsor not shown (see the record) | Phase 1 | Recruiting | Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate... | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06999187) |
| May 11, 2025 | NCT06966024 | Study of DCC-2812 in Participants With Advanced Genitourinary Cancers | Deciphera Pharmaceuticals, LLC | Phase 1 | Recruiting | Renal Cell Carcinoma, Urothelial Carcinoma, Castration-resistant Prostate Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06966024) |
| September 3, 2024 | NCT06582017 | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Nammi Therapeutics Inc | Phase 1 | Recruiting | Ovarian Cancer, Pancreas Cancer, Urothelial Carcinoma, Renal Cell Carcinoma, Hepatocellular Carcinoma, Gastrointestinal... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06582017) |
| June 11, 2024 | NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in... | Zumutor Biologics Inc. | Phase 1 | Recruiting | Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06451497) |
| June 3, 2024 | NCT06439836 | Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy | National Cancer Institute (NCI) | Phase 1 | Recruiting | Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06439836) |
| March 27, 2024 | NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of... | LG Chem | Phase 1 | Recruiting | Non-small Cell Lung Cancer(NSCLC), Head and Neck Squamous Cell Carcinoma(HNSCC), Renal Cell Carcinoma(RCC), Urothelial... | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06332755) |
| March 5, 2024 | NCT06293898 | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | SystImmune Inc. | Phase 1 | Recruiting | Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung... | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06293898) |
| February 21, 2024 | NCT06270706 | A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Pliant Therapeutics, Inc. | Phase 1 | Recruiting | Advanced or Metastatic Solid Tumor | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06270706) |
| October 3, 2022 | NCT05562791 | A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Bladder Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05562791) |
| January 4, 2022 | NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors | Exelixis | Phase 1 | Recruiting | Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid... | 1,394 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05176483) |
| November 4, 2021 | NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | Nurix Therapeutics, Inc. | Phase 1 | Recruiting | Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell... | 345 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05107674) |
| May 7, 2021 | NCT04878029 | Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer | Emory University | Phase 1 | Recruiting | Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04878029) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Memorial Sloan Kettering Cancer Center | 2 |
| IDEAYA Biosciences | 1 |
| Nurix Therapeutics, Inc. | 1 |
| [Exelixis](https://specstream.ai/data/clinical-trials/company/exelixis) | 1 |
| Emory University | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| Zumutor Biologics Inc. | 1 |
| Nammi Therapeutics Inc | 1 |
| SystImmune Inc. | 1 |
| [Shanghai Henlius Biotech](https://specstream.ai/data/clinical-trials/company/shanghai-henlius-biotech) | 1 |
| Myeloid Therapeutics | 1 |
| Generate Biomedicines | 1 |
| [LG Chem](https://specstream.ai/data/clinical-trials/company/lg-chem) | 1 |
| [Genmab](https://specstream.ai/data/clinical-trials/company/genmab) | 1 |
| Pliant Therapeutics, Inc. | 1 |
| National Cancer Institute (NCI) | 1 |
| Huahui Health | 1 |
| [Deciphera Pharmaceuticals, LLC](https://specstream.ai/data/clinical-trials/company/deciphera-pharmaceuticals-llc) | 1 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 1 |
| [ImmunityBio, Inc.](https://specstream.ai/data/clinical-trials/company/immunitybio-inc) | 1 |
| Sutro Biopharma, Inc. | 1 |
| Duboce Biopharmaceuticals, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 20 |
| Spain | 4 |
| China | 4 |
| United Kingdom | 3 |
| Australia | 3 |
| South Korea | 1 |
| Austria | 1 |
| Belgium | 1 |
| France | 1 |
| Germany | 1 |
| Israel | 1 |
| Italy | 1 |
| New Zealand | 1 |
| Poland | 1 |
| Switzerland | 1 |
| Canada | 1 |
| Puerto Rico | 1 |
| Denmark | 1 |
| Japan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Hotel bars in the United States](https://specstream.ai/data/businesses/hotel-bars/united-states)
- [Comfort food restaurants in the United States](https://specstream.ai/data/businesses/comfort-food-restaurants/united-states)
- [West African restaurants in the United States](https://specstream.ai/data/businesses/west-african-restaurants/united-states)
- [Portuguese restaurants in the United States](https://specstream.ai/data/businesses/portuguese-restaurants/united-states)
- [Hydraulic equipment suppliers in the United States](https://specstream.ai/data/businesses/hydraulic-equipment-suppliers/united-states)
- [Computer wholesalers in the United States](https://specstream.ai/data/businesses/computer-wholesalers/united-states)
